RESEARCH MONOGRAPH · KDC-MN-292
Insulin (Research)
Insulin is the foundational pancreatic hormone, the discovery of which (Banting and Best, 1921) won the Nobel Prize and turned type 1 diabetes from a death sentence into a chronic condition. It binds the insulin receptor (a tyrosine kinase), triggering glucose uptake by muscle and fat, glycogen synthesis in liver and muscle, fat storage, and protein synthesis. Recombinant human insulin (Humulin, 1982) was the first FDA-approved recombinant pharmaceutical. In research, insulin is also a key probe for metabolic and anabolic biology, and has been studied for cognition (intranasal delivery) in Alzheimer disease. Recreational use by bodybuilders is high-risk: hypoglycemia is fast, severe, and can kill. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Peptide hormone (51-amino-acid disulfide-linked dipeptide)
The pancreatic peptide hormone insulin; the foundational glucose-regulatory hormone and a research probe for metabolic and anabolic biology.
Abstract
Insulin (CAS 9004-10-8; A-chain 21 amino acids, B-chain 30 amino acids; total molecular weight approximately 5808 Da for human insulin) is the pancreatic peptide hormone discovered by Banting and Best in 1921 (Nobel Prize 1923) and synthesized as recombinant human insulin (Humulin) in 1982 by Genentech, the first FDA-approved recombinant pharmaceutical. Pharmacologically, insulin binds the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) with substantially higher affinity for IR. Receptor binding triggers tyrosine kinase activation of IRS-1/2 and downstream PI3K-Akt signaling, regulating glucose uptake (GLUT4 translocation), glycogen synthesis, lipogenesis, and protein synthesis. Modern formulations include rapid-acting analogs (lispro, aspart, glulisine), regular insulin, intermediate (NPH), long-acting (glargine, detemir, degludec), and ultra-long-acting (degludec). Approved indications: type 1 diabetes (essential), type 2 diabetes (when oral agents fail). The principal safety risk is hypoglycemia, severe enough to cause neuronal injury or death; insulin is among the leading drug-related causes of medical emergency department visits. Recreational anabolic use has been documented but is associated with high acute mortality. Used as the canonical metabolic hormone in academic biology.
Mechanism of action
Insulin receptor agonist; tyrosine kinase activation, PI3K-Akt signaling, GLUT4 translocation, glycogen and lipid synthesis, protein synthesis.
Reported research dose ranges
Clinical individualized; basal-bolus typically 0.5 to 1 IU/kg total. Recreational use is high-risk.
References
- Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922.
- Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001.
- Owens DR, et al. Insulin analogues: structure, properties, and clinical use. Diabetes Metab Res Rev 2001.
Read the full monograph
The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.